Plain Language Summary {#S0001}
======================

Diabetic retinopathy (DR) is a sight-threatening disease affecting millions of people with diabetes. Left untreated, it can slowly become more severe until vision is impaired or lost completely.

Ranibizumab is an effective treatment for diabetic macular edema (DME) and proliferative DR, producing improvements in vision and a decrease in DME and DR severity in many patients. An earlier study using a computer model estimated that monthly ranibizumab for 2 years could reduce the number of people with visual impairment or blindness due to DR by 45% and 75%, respectively.

When the same model was used to analyze the effect of monthly ranibizumab on the number of people with DR worsening or improvement, it estimated that the number of people who would worsen from a moderately severe to more severely sight-threatening form of DR would be reduced by 95%. This model also estimated that the number of people who would experience an improvement in DR severity would increase by nearly 7-fold (682%).

The results from this study build upon the results of earlier studies to suggest ranibizumab has the potential to provide meaningful benefits to large numbers of people with DR.

Introduction {#S0002}
============

Diabetic retinopathy (DR) is a vision-threatening microvascular complication of type 1 and type 2 diabetes mellitus.[@CIT0001] It affects \~93 million people worldwide and is a leading cause of new-onset blindness.[@CIT0002]--[@CIT0005] Patients with either non-proliferative DR (NPDR) or proliferative DR (PDR) can develop diabetic macular edema (DME) which, if left untreated, is a major cause of vision impairment and legal blindness in patients with DR. In the United States from 2005 to 2008, 4.2 million adults with diabetes aged ≥40 years had DR; of these, 655,000 patients had advanced vision-threatening DR.[@CIT0005]

Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds and inhibits the biologic activity of all isoforms of human vascular endothelial growth factor (VEGF)-A. Ranibizumab 0.3 mg was approved by the US Food and Drug Administration for the treatment of DME in 2012 and for DR in patients with DME in 2015. In 2017, the US Food and Drug Administration broadened the DR indication, approving ranibizumab for the treatment of DR with or without DME. Evidence to support these approvals included the RIDE and RISE Phase III clinical trials (NCT00473382 and NCT00473330), which demonstrated that intravitreous ranibizumab every 4 weeks resulted in substantial visual acuity (VA) gains, on average, in patients with DME over 2 years, which were maintained through year 3.[@CIT0006],[@CIT0007] Additional supporting evidence for the broader DR indication was provided by the Diabetic Retinopathy Clinical Research (DRCR) Network Protocol S study (NCT01489189), which demonstrated the efficacy of ranibizumab for DR in patients with and without DME.[@CIT0008]

A model created by Varma et al based on the RIDE/RISE data and DRCR Network trials estimated that, in Hispanic and non-Hispanic white individuals with center-involved DME, monthly ranibizumab 0.3 mg for 2 years potentially would reduce the number with visual impairment (VA worse than 20/40 in the better-seeing eye) by 45% (95% simulation interval \[SI\], 36--53%) and the number with legal blindness (VA 20/200 or worse in the better-seeing eye) by 75% (95% SI, 58--88%).[@CIT0009] The study reported here uses the same model developed by Varma et al[@CIT0009] to estimate the potential impact of monthly ranibizumab (0.3 or 0.5 mg) on improvement or worsening of DR severity, rather than the resultant vision loss, in Hispanic and non-Hispanic white persons in the United States with center-involved DME causing vision impairment. An assessment of the effect of treatment on DR severity is important because of the well-documented relationship between increasing DR severity and health-related quality of life scores.[@CIT0010]--[@CIT0012] Increasing DR severity can have an impact on vision-related quality of life before changes in VA can be detected.[@CIT0012]

Materials and Methods {#S0003}
=====================

Hispanic and non-Hispanic white persons in the United States in 2010 aged ≥45 years with center-involved DME with VA 20/32 or worse who would be eligible for ranibizumab treatment ([Figure 1](#F0001){ref-type="fig"}) were included based on the model previously described by Varma et al.[@CIT0009] The model included only Hispanic and non-Hispanic white persons with access to health insurance (and hence, presumably to ranibizumab treatment) because the incidence of DME was not available in other racial or ethnic groups. The present study simulated the DR severity levels of these persons over 2 years in the better-seeing eye only. Because this study was a population-based simulation, neither institutional review board nor ethics committee approval was required.Figure 1Estimated total number of Hispanic and non-Hispanic white persons aged ≥45 years with DR in the presence of center-involved DME causing vision of 20/32 or worse who would be considered for ranibizumab treatment in the United States in 2010. Numbers in parentheses represent the 95% SI. Reprinted from *Ophthalmology*, 122(5), Varma R, Bressler NM, Doan QV, et al. Visual impairment and blindness avoided with ranibizumab in Hispanic and non-Hispanic white persons with diabetic macular edema in the United States. 982--989, Copyright (2015), with permission from Elsevier.[@CIT0009]**Abbreviations:** DME, diabetic macular edema; DR, diabetic retinopathy; SI, simulation interval.

Estimate of Persons with Center-Involved DME for Whom Ranibizumab Treatment Would Be Considered {#S0004}
===============================================================================================

The total number of Hispanic and non-Hispanic white persons with DR in the presence of center-involved DME with vision impairment in the United States was estimated using a stepwise method ([Figure 1](#F0001){ref-type="fig"}).

First, 2010 US Census Bureau data were used to stratify non-Hispanic white and Hispanic persons aged ≥45 years into 10-year age groups.[@CIT0013],[@CIT0014] In step 2, the race/ethnic and age group--specific prevalence of self-reported diabetes mellitus was determined from National Health and Nutrition Examination Survey 2005--2008 data.[@CIT0015] In step 3, the 1-year incidence of center-involved DME for non-Hispanic white persons was determined from the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR)[@CIT0016] and for Hispanics from the Los Angeles Latino Eye Study (LALES).[@CIT0017] The proportion of incident eyes with center-involved DME with VA 20/32 or worse Snellen equivalent (best-corrected VA letter score ≤78) was estimated using data from LALES for both Hispanic and non-Hispanic white persons because equivalent data were not available from WESDR. Patients with DME that did not involve the center of the macula or with VA better than 20/32 Snellen equivalent in the incident eye were excluded because this was not the population evaluated in the studies used for this modeling (RIDE/RISE, Protocol I \[NCT00444600\], and Protocol S). In step 4, the percentage of uninsured persons by age and race/ethnic groups was determined from 2010 US Census Bureau data.[@CIT0018],[@CIT0019] Persons without health insurance were excluded, based on the assumption that they would not have access to ranibizumab. Lastly (step 5), the total number of persons eligible for treatment was derived by summing across all age and race/ethnic groups. This final number was used to simulate treatment with and without ranibizumab 0.3 and 0.5 mg.

Estimated Rates of DR Severity Level Change and Selected Clinical Events {#S0005}
========================================================================

The model was conducted as a 2-dimensional Monte Carlo simulation to account for various sources of patient-level variability and parameter uncertainty. To achieve stable rates, 300 averages of 215 simulated patients based on the size of the trial population were sampled using TreeAge Pro (TreeAge Software, Inc., Williamstown, MA, USA). The population-level simulation was carried out in \@Risk 6.1.1 (Palisade Corporation, Ithaca, NY, USA) using 10,000 iterations. For each simulated patient, the DR severity level of the incident eye at baseline was sampled from the DR severity level distribution of patients in the DRCR Network (Protocol I; [Table 1](#T0001){ref-type="table"}).[@CIT0006],[@CIT0013],[@CIT0015]--[@CIT0022] The DR severity level change over 2 years was conditioned on the patient's baseline DR severity level. Changes in DR severity level (scale is shown in [Table 2](#T0002){ref-type="table"})[@CIT0023],[@CIT0024] of the incident eye after 2 years were estimated, with and without monthly ranibizumab 0.3 or 0.5 mg, using patient-level data from the RIDE/RISE trials.[@CIT0006] The model also tracked any vitreous hemorrhage, panretinal photocoagulation (PRP), or vitrectomy for PDR, which are hereafter referred to as "clinical events related to PDR" because these events could represent a clinically relevant worsening of DR severity to the proliferative form in the absence of photographic documentation. DR severity in the fellow (non-study) eye was not evaluated.Table 1Specification for Model Parameter InputsModel ParameterValue (Uncertainty or Variability)Source and NotesPopulation size in 2010, no. Non-Hispanic white persons, by age group (years)2010 US Census data[@CIT0001]  45--5431,141,170  55--6427,277,532  65--7416,940,823  ≥7515,268,608  Total90,628,133 Hispanic persons, by age group (years)2010 US Census data[@CIT0001]  45--545,463,528  55--643,213,817  65--741,648,718  ≥751,132,906  Total11,458,969Prevalence of diabetes mellitus, % (SE) Non-Hispanic white persons, by age group (years)National Health and Nutrition Examination Survey 2005--2008 data[@CIT0002]  45--546.4 (0.9)  55--6410.8 (1.3)  65--7418.1 (1.8)  ≥7514.4 (1.4) Hispanic persons, by age group (years)National Health and Nutrition Examination Survey 2005--2008 data[@CIT0002]  45--5414.4 (2.6)  55--6424.6 (3.1)  65--7429.3 (5.0)  ≥7525.1 (4.8)Annual incidence of center-involved DME, mean (SE) Non-Hispanic white persons0.01308 (0.00271)WESDR[@CIT0003] Hispanic persons0.01587 (0.00245)LALES[@CIT0004]Proportion of incident eyes with center-involved DME that have VA of 20/32 or worse (BCVA ≤78 letter score) (%)24.4LALES[@CIT0004]Annual incidence of center-involved DME with VA of 20/32 or worse (BCVA ≤78 letter score), mean (SE) Non-Hispanic white persons0.00319 (0.00066)Derived based on information from WESDR and LALES[@CIT0003],[@CIT0004] Hispanic persons0.00387 (0.00060)Derived based on information from WESDR and LALES[@CIT0003],[@CIT0004]US population without any health insurance, % (SE) Non-Hispanic white persons, by age group (years)Current Population Survey[@CIT0005],[@CIT0006]  45--5413.5 (10.0)  55--6411.0 (9.7)  65--741.3 (4.5)  ≥750.6 (3.2) Hispanic persons, by age group (years)Current Population Survey[@CIT0005],[@CIT0006]  45--5437.0 (40.9)  55--6431.4 (50.1)  65--7410.1 (44.2)  ≥756.4 (46.0)Mortality rate Age-specific mortality rate in the United States^a^United States Life Tables[@CIT0007] Relative rate of mortality (diabetics vs non-diabetics)2.31Gregg 2007[@CIT0008]; this factor was applied to the overall mortality rate to derive a diabetes-specific mortality rateProportion of patients with incident center-involved DME with VA of 20/32 or worse that also had DME in the fellow eye with VA of 20/32 or worse at baseline (%)60.6Based on the proportion of fellow eyes in the RIDE and RISE trials that had DME and VA of 20/32 or worse (BCVA ≤78 letter score)[@CIT0009]Probability of developing center-involved DME in fellow eye, monthly (SE)0.0038 (0.0013)18.3% over 4 years based on LALES[@CIT0004]; probability for Hispanic persons was also used for non-Hispanic white personsProbability of ranibizumab discontinuation (monthly)0.0068RIDE and RISE[@CIT0009]Baseline DR severity level (%) 10.5DRCR Network (Protocol I)[@CIT0010] 20.9 39.7 412.5 536.6 67.9 727.1 82.9 91.9 100[^1][^2] Table 2Definition of DR Severity Level Based on the ETDRS-DRSS Scoring Using Fundus Photography^a^DR Severity LevelDR Severity Defined Using the ETDRS Description1DR severity level 10, 12 (DR absent)2DR severity level 14A--14C, 14Z, 15, 20 (DR questionable, microaneurysms only)3DR severity level 35A--35F (mild NPDR)4DR severity level 43A, 43B (moderate NPDR)5DR severity level 47A--47D (moderately severe NPDR)6DR severity level 53A--53E (severe NPDR)7DR severity level 60, 61A, 61B (mild PDR)8DR severity level 65A--65C (moderate PDR)9DR severity level 71A--71D (high-risk PDR)10DR severity level 75 (high-risk PDR)[^3][^4]

To determine the population-level impact of treatment for each outcome, the difference in the number of patients with and without ranibizumab was calculated along with the percentage change. The risk of death was applied using base US age-specific mortality rates adjusted for additional mortality risk for persons with diabetes.[@CIT0022] The simulation also accounted for the patient's risk of treatment discontinuation every 4 weeks. While off treatment, it was assumed that there were no further changes in DR severity level; as such, the DR severity level remained constant from the time of discontinuation to month 24.

Outcomes Examined {#S0006}
=================

The outcomes evaluated by the model are detailed in [Table 3](#T0003){ref-type="table"}. The primary analysis was conducted with 0.3-mg treatment, with the results for 0.5-mg treatment provided in [[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=236636.docx)]{.ul}. As previously reported, the RIDE/RISE DR severity outcomes for the 2 doses were similar.[@CIT0024],[@CIT0025]Table 3DR Severity Outcomes for Ranibizumab 0.3 mg at 2 Years Based on Baseline DR SeverityDR Severity Level at Baseline^a^DR Severity Outcome at 2 YearsDR worsening outcomes≤4Worsened by ≥2 DR severity levels, or did not worsen by ≥2 DR severity levels but developed either vitreous hemorrhage, or received PRP, or vitrectomy for PDR≤5Worsened to DR severity level ≥6≤5Worsened to DR severity level ≥6 and developed vitreous hemorrhage, or received PRP, or vitrectomy for PDR≤5Worsened to DR severity level 6≤5Worsened to DR severity level ≥7≤5Worsened to DR severity level ≥7 and developed vitreous hemorrhage, or received PRP, or vitrectomy for PDR≤6Worsened to DR severity level ≥7, or did not worsen to DR severity level ≥7 but developed vitreous hemorrhage, or received PRP, or vitrectomy for PDR≤6Worsened to DR severity level ≥7 and developed vitreous hemorrhage, or received PRP, or vitrectomy for PDR≤6Worsened by ≥2 DR severity levels6Worsened to DR severity level ≥7≥7DR worsening defined as development of vitreous hemorrhage, or received PRP, or vitrectomy for PDRDR improvement outcomes≤6Improved by ≥2 DR severity levels, and no vitreous hemorrhage, PRP, or vitrectomy for PDR≤6Improved by ≥2 DR severity levels≥6Improved to DR severity level ≤5Any DR severity levelImproved by ≥2 DR severity levels from any baseline DR severity level and no vitreous hemorrhage, PRP, or vitrectomy for PDR[^5][^6]

The 4 outcomes judged to be most clinically relevant were included in the analysis. The first and second outcomes were the number of persons with moderately severe NPDR or less severe DR (level ≤5) at baseline who were predicted to worsen to severe NPDR (level ≥6) or PDR (level ≥7) over 2 years. The third outcome was the number of persons without PDR (level ≤6) at baseline who were predicted to worsen to PDR (level ≥7) over 2 years. The fourth outcome was the estimated number of persons with severe NPDR or better (level ≤6) at baseline who were predicted to improve by ≥2 DR severity levels over 2 years. In addition to the specified level of DR severity worsening/improvement, all outcomes were considered in combination with the occurrence of the aforementioned clinical events related to PDR. Results for other outcomes are provided in [[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=236636.docx)]{.ul}.

Results {#S0007}
=======

As previously reported, the model estimated that 37,274 Hispanic and non-Hispanic white persons in the United States in 2010 aged ≥45 years with DR and center-involved DME causing vision impairment could be eligible for ranibizumab treatment ([Figure 1](#F0001){ref-type="fig"}).[@CIT0009] Treatment with monthly ranibizumab 0.3 mg could potentially result in improvements for all DR-related outcomes examined in the model ([Table 4](#T0004){ref-type="table"}, [[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=236636.docx)]{.ul}).Table 4DR Progression-Related Outcomes for Ranibizumab 0.3 mg versus No Ranibizumab at 2 YearsDR Severity Level at BaselineDR Severity Outcome at 2 YearsTreatmentCases Avoided\
(95% SI)% Change from No Treatment (95% SI)No Ranibizumab (95% SI)Ranibizumab 0.3 mg (95% SI)DR worsening outcomes≤5Worsened to DR severity level ≥6 and developed vitreous hemorrhage, or received PRP, or vitrectomy for PDR469 (209--832)20 (0--81)450^a^ (187--807)95% reduction (80--100%)≤5Worsened to DR severity level ≥7 and developed vitreous hemorrhage, or received PRP, or vitrectomy for PDR437 (197--778)19 (0--81)418 (173--758)95% reduction (79--100%)≤6Worsened to DR severity level ≥7, and developed vitreous hemorrhage, or received PRP, or vitrectomy for PDR604 (289--1021)19 (0--80)585 (271--997)97% reduction (85--100%)DR improvement outcomes≤6Improved by ≥2 DR severity levels1706 (989--2617)13,042 (8199--18,279)11,337 (7087--16,031)^b^682% increase (478--967%)[^7][^8]

Without ranibizumab treatment, 469 persons (95% SI, 209--832) with moderately severe NPDR or less severe DR (level ≤5) at baseline were predicted to develop severe NPDR or more severe DR (level ≥6) and potentially experience a clinical event related to PDR over 2 years. Treatment with monthly ranibizumab 0.3 mg could potentially reduce this number to 20 (95% SI, 0--81), reducing the number of patients experiencing this level of DR severity worsening to 450 (95% SI, 187--807; value rounded up, see [Table 4](#T0004){ref-type="table"}); equivalent to a 95% reduction over 2 years (95% SI, 80--100%; [Table 4](#T0004){ref-type="table"}).

Worsening of DR severity from moderately severe NPDR or less severe DR (level ≤5) at baseline to PDR (level ≥7) plus a clinical event related to PDR over 2 years was predicted in 437 persons (95% SI, 197--778) who did not receive ranibizumab. Treatment with monthly ranibizumab 0.3 mg was predicted to reduce this number to 19 (95% SI, 0--81), potentially reducing the number of patients experiencing this level of DR severity worsening by 418 (95% SI, 173--758); equivalent to a 95% (95% SI, 79--100%) reduction over 2 years ([Table 4](#T0004){ref-type="table"}).

The model predicted that 604 persons (95% SI, 289--1021) who did not receive ranibizumab would worsen from severe NPDR or less severe DR (level ≤6) at baseline to PDR (level ≥7) and potentially experience a clinical event related to PDR over 2 years. Treatment with monthly ranibizumab 0.3 mg could potentially reduce this number to 19 (95% SI, 0--80), potentially reducing the number of patients experiencing this level of DR severity worsening (95% SI, 271--997) by 585; equivalent to a 97% (95% SI, 85--100%) reduction over 2 years ([Table 4](#T0004){ref-type="table"}).

With monthly ranibizumab 0.3 mg, 13,042 persons (95% SI, 8199--18,279) with severe NPDR or less severe DR (level ≤6) at baseline were expected to improve by ≥2 DR severity levels over 2 years. This is compared with 1706 persons (95% SI, 989--2617) without ranibizumab, such that ranibizumab treatment resulted in an estimated 6-fold (682%; 95% SI, 478--967%) improvement over 2 years ([Table 4](#T0004){ref-type="table"}). Similar patterns were observed for monthly ranibizumab 0.5 mg across all levels of severity of DR that were examined ([[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=236636.docx)]{.ul}).

Discussion {#S0008}
==========

This study, based on a previously developed population-based model,[@CIT0009] predicts that treatment with monthly ranibizumab 0.3 or 0.5 mg has the potential to substantially reduce the number of patients experiencing worsening DR severity within 2 years among the 37,274 Hispanic and non-Hispanic white persons with center-involved DME for whom ranibizumab treatment would be considered. Furthermore, the model predicts that treatment of these patients with ranibizumab could markedly increase the number of patients experiencing improvement in DR severity.

The results of this study are supported by an exploratory analysis of data from the RIDE/RISE trials, which demonstrated that ranibizumab reduced the risk of worsening of DR severity, with improvement in DR severity seen in many patients.[@CIT0024],[@CIT0025] Among patients who received ranibizumab 0.3 or 0.5 mg every 4 weeks (n=468), 13.2% and 14.5% of patients, respectively, had an ≥3 Early Treatment Diabetic Retinopathy Study severity level improvement from baseline at 2 years, compared with 1.3% of sham patients (n=239; *P*\<0.001). Furthermore, 37.2% and 35.9% of patients, respectively, had an ≥2 Early Treatment Diabetic Retinopathy Study severity level improvement over the same period, compared with 5.4% of sham patients (*P*\<0.001).[@CIT0024] Similar proportions of ranibizumab-treated patients maintained this level of improvement through to 3 years post baseline.[@CIT0025] Recently, the clinical relevance of these changes has been explored in a post hoc analysis of patients enrolled in the RIDE/RISE trials, showing that improvements in DR severity were associated with greater VA gains, improved contrast sensitivity, and increased likelihood of resolution of macular edema.[@CIT0026]

In addition, an exploratory analysis by Bressler et al from the DRCR Network Protocol I study of 792 eyes from patients with center-involved DME causing VA impairment suggested that ranibizumab (0.5 mg every 4 weeks for 12 weeks, then as needed with either prompt or deferred \[≥24 weeks\] laser) was also associated with a reduced risk of DR worsening in eyes with and without PDR versus sham with prompt laser.[@CIT0027] Similar findings were noted in uncontrolled case series with ranibizumab[@CIT0028],[@CIT0029] as well as other anti-VEGF agents used for treatment of DME.[@CIT0030] Additionally, the 2-year results of the DRCR Network Protocol S study comparing PRP with ranibizumab treatment for PDR demonstrated non-inferiority of ranibizumab (0.5 mg up to every 4 weeks based on a structured re-treatment program) to PRP (completed in 1--3 visits, plus ranibizumab for DME); notably, 53% of patients in the PRP group received ranibizumab injections for DME.[@CIT0008] The findings of this study suggest that anti-VEGF therapy with ranibizumab may have additional utility as a treatment option for PDR when it has developed, including preservation of peripheral visual field that occurs following PRP and a marked reduction in the occurrence of macular edema in patients with PDR without concurrent macular edema at the time of diagnosis.

Results from LALES demonstrated that patients with more severe DR had worse health-related quality of life scores, based on results from the National Eye Institute Visual Function Questionnaire-25 and Medical Outcomes Study 12-Item Short Form Health Survey.[@CIT0012] A steep decline in patient-reported visual function (driving difficulty) and health-related quality of life was noted once both eyes were affected by moderate NPDR (level 4). Results from WESDR demonstrated that the National Eye Institute Visual Function Questionnaire-25 score was associated most closely with central vision.[@CIT0011] As such, these results indicate that DR impacts patient-reported visual function, which may be related, at least in part, to vision loss. A decline in vision-related functioning with increasing DR severity can be detected before changes in VA can be measured.[@CIT0012] A series of focus groups involving patients with mild, moderate, or severe NPDR, or PDR highlighted a substantial impact of DR-associated visual impairment on independence, mobility, leisure, and self-care activities (including diabetes management).[@CIT0010] As such, preserving visual function through reducing DR worsening or improving DR severity with ranibizumab for treatment of DME has the potential to greatly improve patient well-being and function (potentially reducing health care resource utilization).[@CIT0031]

This study is subject to several limitations. The model only included data from Hispanic and non-Hispanic white persons with center-involving DME and estimated their response in the best-seeing eye only based on the results of randomized controlled clinical trials of ranibizumab. Consequently, it is not known whether the findings can be generalized to other patient groups, other anti-VEGF agents, other settings, or analyses based on the worse-seeing eye. It should be noted, however, that the groups included do comprise a large percentage of the overall population and there is no evidence of a difference in response to anti-VEGF therapy based on ethnicity[@CIT0032],[@CIT0033] or presence versus absence of DME.[@CIT0008] The results of the Protocol T study also suggest that the different anti-VEGF agents have similar effects on DR severity level.[@CIT0034] Secondly, the model did not differentiate between patients with type 1 versus type 2 diabetes. Patients with either type 1 or type 2 diabetes are commonly included in clinical trials, and there is no evidence of a differential response to treatment based on diabetes type. Thirdly, only incident (not prevalent) cases of DR were included; considering prevalent cases should increase the number of patients achieving the study outcomes substantially. The model only considered incident cases of center-involved DME with DR for 1 year (2010), meaning that cases that may have arisen in the second year were not included. Fourthly, only patients with health insurance were included in the study, which could have resulted in an underestimation of the number of patients who have access to ranibizumab treatment after introduction of the Affordable Care Act. Fifthly, although the model took into account the patients' risk of ranibizumab discontinuation every 4 weeks, it was assumed that there were no further changes in DR severity level from the time of discontinuation through month 24. In Protocol I, Protocol S, and the RIDE/RISE open-label extension, DR severity improvements with ranibizumab were maintained with a marked reduction in treatment frequency for long periods of time (up to 5 years in Protocol I) after the end of monthly treatment, suggesting that the risk of progression may remain low for up to 18 months after treatment discontinuation.[@CIT0008],[@CIT0035],[@CIT0036] This may not be true for all patients, or among different anti-VEGF agents, however, and should be considered a limitation of the study. Sixthly, the model did not include the potential effect of adverse effects from the injections. In these studies, the adverse event rate was low and unlikely to have a substantial effect on DR severity. Finally, this study did not examine the quality of life or economic impacts of monthly ranibizumab injections for the patient versus the benefits of the effects of treatment on DR worsening.

In conclusion, the findings of this simulation model show that, in patients with center-involved DME causing vision impairment, ranibizumab has the potential to reduce the number of patients with worsening DR severity, and to increase the number of patients with improvements in DR severity, within the US Hispanic and non-Hispanic white populations. This compliments and builds upon our previous study that estimated that ranibizumab treatment could significantly reduce the number of these patients developing visual impairment or progressing to legal blindness.[@CIT0009] Together, these impacts have the potential to improve daily functioning and independence in patients, many of whom may be of working age. It might also reduce the need for PRP or other interventions required for the treatment of worsening DR severity and its complications.[@CIT0037] The potential economic impact and overall cost-effectiveness remain to be investigated.
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[^1]: **Note:** ^a^See referenced data source.

[^2]: **Abbreviations:** BCVA, best-corrected visual acuity; DME, diabetic macular edema; DR, diabetic retinopathy; DRCR, Diabetic Retinopathy Clinical Research; LALES, Los Angeles Latino Eye Study; SE, standard error; VA, visual acuity; WESDR, Wisconsin Epidemiologic Study of Diabetic Retinopathy.

[^3]: **Note:** ^a^DR severity was graded using the ETDRS-DRSS scale developed previously using fundus photographs obtained from patients at screening visits.[@CIT0001],[@CIT0002]

[^4]: **Abbreviations:** DR, diabetic retinopathy; DRSS, Diabetic Retinopathy Severity Scale; ETDRS, Early Treatment Diabetic Retinopathy Study; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy.

[^5]: **Note:** ^a^DR severity level as described in [Table 2 ](#T0002){ref-type="table"}was defined using ETDRS-DRSS scoring.[@CIT0023]

[^6]: **Abbreviations:** DR, diabetic retinopathy; DRSS, Diabetic Retinopathy Severity Scale; ETDRS, Early Treatment Diabetic Retinopathy Study; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation.

[^7]: **Notes:** ^a^Inconsistency due to rounding. ^b^In outcomes with DR improvement, results were how many more persons improved with ranibizumab.

[^8]: **Abbreviations:** DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation; SI, simulation interval.
